Pemphigus Vulgaris - Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Pemphigus Vulgaris - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Discovery and Unknown stages are 1, 4, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Companies Mentioned

  • arGEN-X BV
  • Biogen Inc
  • HanAll Biopharma Co Ltd
  • Immunomedics Inc
  • Novartis AG
  • Principia Biopharma Inc

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Pemphigus Vulgaris - Overview
  4. Pemphigus Vulgaris - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Pemphigus Vulgaris - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Pemphigus Vulgaris - Companies Involved in Therapeutics Development
  16. arGEN-X BV
  17. Biogen Inc
  18. HanAll Biopharma Co Ltd
  19. Immunomedics Inc
  20. Novartis AG
  21. Principia Biopharma Inc
  22. Pemphigus Vulgaris - Drug Profiles

For more information about this report visit https://www.researchandmarkets.com/research/948nbt/pemphigus?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs